Source: International Congress 2016 – Clinical and molecular studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Eric D. Bateman (Cape Town, South Africa), Eric D. Bateman, Alfredo Guerreros, Florian Brockhaus, Bjoern Holzhauer, Abhijit Pethe, Richard Kay, Robert G. Townley. Efficacy and safety of fevipiprant (QAW039) in patients with atopic asthma uncontrolled on low-dose ICS therapy. Eur Respir J 2016; 48: Suppl. 60, 1981

Member's Comments

No comment yet.

Related content which might interest you: Adherence and effectiveness of omalizumab treatment in severe allergic asthma patients: Do the patients like injectable treatment? Source: Annual Congress 2013 –Treatment of asthma Year: 2013 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Safety and tolerability of acute dosing of beta-blockers in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Evaluation of methotrexate in the treatment of severe asthma Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Experience with omalizumab in patients with moderate and severe asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Comparative effectiveness of paediatric asthma step-up options: Increasing ICS dose vs adding separate LABA Source: International Congress 2014 – Paediatric asthma: what is new for the clinician? Year: 2014 Ultra-rush sublingual immunotherapy: Safety of use for patients with various allergic manifestations Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Interim analysis of a prospective study investigating oral corticosteroid (OCS) use in omalizumab treated severe allergic asthma patients: APEX II study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014